- Home
- FIGS vs AVBP Comparison
FIGS vs AVBP Comparison
Compare FIGS & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- AVBP
- Stock Information
- Founded
- FIGS 2013
- AVBP 2021
- Country
- FIGS United States
- AVBP United States
- Employees
- FIGS N/A
- AVBP N/A
- Industry
- FIGS Apparel
- AVBP
- Sector
- FIGS Consumer Discretionary
- AVBP
- Exchange
- FIGS Nasdaq
- AVBP NYSE
- Market Cap
- FIGS 1.0B
- AVBP 925.7M
- IPO Year
- FIGS 2021
- AVBP 2024
- Fundamental
- Price
- FIGS $6.01
- AVBP $25.31
- Analyst Decision
- FIGS Hold
- AVBP Strong Buy
- Analyst Count
- FIGS 6
- AVBP 5
- Target Price
- FIGS $5.35
- AVBP $36.80
- AVG Volume (30 Days)
- FIGS 2.1M
- AVBP 151.8K
- Earning Date
- FIGS 02-26-2025
- AVBP 02-02-2025
- Dividend Yield
- FIGS N/A
- AVBP N/A
- EPS Growth
- FIGS N/A
- AVBP N/A
- EPS
- FIGS 0.05
- AVBP N/A
- Revenue
- FIGS $548,644,000.00
- AVBP N/A
- Revenue This Year
- FIGS $1.64
- AVBP N/A
- Revenue Next Year
- FIGS $3.07
- AVBP N/A
- P/E Ratio
- FIGS $111.71
- AVBP N/A
- Revenue Growth
- FIGS 0.55
- AVBP N/A
- 52 Week Low
- FIGS $4.30
- AVBP $14.35
- 52 Week High
- FIGS $7.06
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- FIGS 53.42
- AVBP 43.45
- Support Level
- FIGS $5.86
- AVBP $23.63
- Resistance Level
- FIGS $6.17
- AVBP $26.54
- Average True Range (ATR)
- FIGS 0.26
- AVBP 1.53
- MACD
- FIGS -0.01
- AVBP -0.10
- Stochastic Oscillator
- FIGS 45.53
- AVBP 34.46
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.